Lincoln Pharmaceuticals: Un-Audited Financial Results For the Quarter and Half Year ended on September 30, 2026
Lincoln Pharmaceuticals (LINCOLN) filed a disclosure titled "Un-Audited Financial Results For the Quarter and Half Year ended on September 30, 2026". The company is valued at about ₹1,102 crore.
What happened
Lincoln Pharmaceuticals (LINCOLN) filed a disclosure with the exchanges on 29 October 2026 at 12:21 PM titled "Un-Audited Financial Results For the Quarter and Half Year ended on September 30, 2026".
Company snapshot
Lincoln Pharmaceuticals is a small-cap company, with a market value of about ₹1,102 crore.
The stock last traded at ₹550.1, against a 52-week range of ₹440–₹770 (28.6% below the high).
Before this filing the shares had moved −7.5% over the month and −5.5% over three months. Average daily turnover over the last 20 sessions was about ₹1.74 crore.
Promoters held 49.78% at the end of Q1 FY27. Foreign institutions owned 4.60% and domestic institutions 0.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 154 | 27.7 | 13.82 |
| Q2 FY26 | 163 | 20 | 9.98 |
| Q3 FY26 | 166 | 28.6 | 14.28 |
| Q4 FY26 | 187 | 11.6 | 5.81 |
| Q1 FY27 | 177 | 36.2 | 18.09 |
What history shows
This is not the company's first results disclosure: BCEIE has 4 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 8.3% on average the next trading day and was down 6.2% on average after five days (4 filings with price data).
Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 13 Aug 2026 | Un-Audited Financial Results For Quarter Ended On 30 June, 2026. | +3.5% | +5.0% |
| 13 Aug 2026 | Board Meeting Outcome for Board Meeting Outcome For Un-Audited… | +3.5% | +5.0% |
| 28 May 2026 | Audited Financial Results For The Quarter And Year Ended 31St March,… | −20.0% | −17.5% |
| 28 May 2026 | Board Meeting Outcome for Board Meeting Outcome For Audited… | −20.0% | −17.5% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 29 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Lincoln Pharmaceuticals Sept-Quarter Consol Net Profit 204.3 Million Rupees
- Lincoln Pharmaceuticals senior quality head resigns over personal reasons
- Lincoln Pharmaceuticals (NSE:LINCOLN): Who Has Resigned From Senior Management?
- Lincoln Pharmaceuticals 32nd AGM: Key Resolutions Passed
- Lincoln Pharmaceuticals Ltd Forms Death Cross Signalling Potential Bearish Trend
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.